Who Qualifies for a GLP-1 Prescription?
GLP-1 receptor agonists are FDA-approved prescription medications, which means you need a licensed healthcare provider to determine whether they're appropriate for you. The qualification criteria are based on a combination of your body mass index (BMI), existing health conditions, and medical history.
The FDA-approved indications for weight management follow a two-tier structure. Adults with a BMI of 30 or higher (classified as obesity) qualify based on BMI alone. Adults with a BMI of 27 to 29.9 (classified as overweight) qualify if they also have at least one weight-related health condition, such as type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, or cardiovascular disease.
The BMI Thresholds Explained
BMI is calculated by dividing your weight in kilograms by the square of your height in meters. While it's an imperfect measurement that doesn't distinguish between muscle and fat mass, it remains the standard screening tool used by insurers and prescribers for GLP-1 eligibility.
| BMI Range | Classification | GLP-1 Eligibility |
|---|---|---|
| Below 27 | Normal / Overweight | Generally not eligible for weight management indication |
| 27 – 29.9 | Overweight | Eligible with at least one weight-related comorbidity |
| 30 – 34.9 | Obesity Class I | Eligible |
| 35 – 39.9 | Obesity Class II | Eligible |
| 40+ | Obesity Class III | Eligible |
If you have type 2 diabetes, you may qualify for GLP-1 medications approved for glycemic control (such as Ozempic or Mounjaro) regardless of your BMI. Weight loss occurs as a secondary benefit in these cases.
Which GLP-1 Medications Are Available in 2026?
The GLP-1 landscape has expanded significantly. For weight management specifically, the FDA-approved options now include Wegovy (semaglutide injection), the Wegovy pill (oral semaglutide 25mg, approved December 2025), Wegovy HD (7.2mg injection, approved March 2026), Zepbound (tirzepatide injection), and Foundayo (orforglipron, approved April 1, 2026). For type 2 diabetes, Ozempic (semaglutide) and Mounjaro (tirzepatide) remain widely prescribed, with weight loss as a well-documented secondary effect.
Foundayo represents a notable addition as the first non-peptide oral GLP-1 that can be taken at any time of day without food or water restrictions. This eliminates the 30-minute fasting requirement associated with the Wegovy pill.
Qualifying Comorbidities
If your BMI falls between 27 and 29.9, you'll need documentation of at least one weight-related health condition. The most commonly accepted qualifying conditions include hypertension (high blood pressure), type 2 diabetes or prediabetes, dyslipidemia (high cholesterol or triglycerides), obstructive sleep apnea, cardiovascular disease or history of cardiac events, non-alcoholic fatty liver disease, osteoarthritis of weight-bearing joints, and polycystic ovarian syndrome (PCOS).
Your healthcare provider will assess these conditions and document them as part of any prescription or prior authorization request.
How Telehealth Prescriptions Work
Telehealth platforms have become one of the most accessible pathways to GLP-1 prescriptions. The process typically follows three steps: you complete an online health assessment covering your medical history, current medications, and weight-loss goals; a licensed physician reviews your information and may ask follow-up questions via messaging or video; and if clinically appropriate, the physician writes a prescription that's filled by a pharmacy and shipped to your door.
Most telehealth platforms can complete this process within 24 to 72 hours. Some prescribe FDA-approved brand-name medications, while others prescribe compounded formulations through FDA-registered pharmacies.
What If Your BMI Is Below 27?
GLP-1 medications are not currently FDA-approved for weight management in individuals with a BMI below 27. The clinical trials that established safety and efficacy were conducted in populations meeting the BMI thresholds described above. Using these medications at lower body weights raises proportionally greater concerns about muscle loss, nutritional adequacy, and gastrointestinal side effects on a lighter frame.
If your BMI is below 27 but you have type 2 diabetes, you may still qualify through the diabetes indication. Otherwise, your healthcare provider can discuss alternative approaches to weight management.
What to Expect at Your First Visit
Whether in person or via telehealth, your initial consultation should cover a review of your weight history and previous weight-loss attempts, current BMI measurement and documentation, a comprehensive list of current medications and supplements, screening for contraindications (history of pancreatitis, medullary thyroid cancer, or Multiple Endocrine Neoplasia syndrome type 2), discussion of treatment goals and realistic expectations, and a plan for starting dose and titration schedule.
Be prepared to share your medical records if you have relevant documentation from other providers. The more complete your information, the smoother the prescribing process.
Bottom Line
Getting a GLP-1 prescription in 2026 is more straightforward than ever, with multiple medications, delivery formats (injection, oral pill, gum), and access pathways (in-person, telehealth, manufacturer-direct). The fundamental requirement hasn't changed: a BMI of 30 or higher, or a BMI of 27 or higher with a qualifying comorbidity, evaluated by a licensed healthcare provider who determines the medication is clinically appropriate for you.